Get the Stockscreener App
5.25
0.94%
-0.05
After Hours:
5.23
-0.02
-0.38%
Savara Inc stock is traded at $5.25, with a volume of 922.98K.
It is down -0.94% in the last 24 hours and down -5.58% over the past month.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
See More
Previous Close:
$5.30
Open:
$5.33
24h Volume:
922.98K
Relative Volume:
0.59
Market Cap:
$1.08B
Revenue:
-
Net Income/Loss:
$-118.84M
P/E Ratio:
-9.8241
EPS:
-0.5344
Net Cash Flow:
$-101.06M
1W Performance:
+4.58%
1M Performance:
-5.58%
6M Performance:
+30.27%
1Y Performance:
+60.06%
1-Day Range:
$5.07
$5.44
1-Week Range:
$4.835
$5.44
52-Week Range:
$1.89
$7.005
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
5.25 | 1.09B | 0 | -118.84M | -101.06M | -0.5344 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Savara (SVRA) to Release Earnings on Tuesday - MarketBeat
SVRA stock slips post-market after FDA delays decision on pulmonary therapy - MSN
Savara Grants Equity Awards to 24 New Employees - MyChesCo
US High Growth Tech Stocks To Watch - Sahm
Savara Inc. ticks higher amid takeover speculation - MSN
FDA Extends Review of Savara’s Molgramostim Application to November - MyChesCo
Savara to Present Molgramostim Data at ATS 2026 Conference - MyChesCo
Assessing Savara (SVRA) Valuation After FDA Extends Priority Review For Molgramostim - Yahoo Finance
Savara’s FDA Review Extension Keeps Molgramostim Thesis Intact But Delayed - Sahm
Savara Inc ($SVRA) CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Savara Inc SEC Filing - Stock Titan
Savara (NASDAQ: SVRA) seeks big share boost and equity plan expansion - Stock Titan
Savara (NASDAQ:SVRA) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Savara (SVRA) Stock: Pricing Efficiency Review | Q4 2025: EPS Misses EstimatesLow Growth - Cổng thông tin điện tử tỉnh Lào Cai
SVRA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Savara Inc. (NASDAQ:SVRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Savara (SVRA) Stock: Why It Could Double (Mini Selloff) 2026-04-20Profit Potential - Cổng thông tin điện tử tỉnh Lào Cai
Savara reports 2025 results, advances MOLBREEVI toward approval - MSN
Savara Announces New Employment Inducement GrantApril 17, 2026 - BioSpace
FY2026 EPS Estimates for Savara Decreased by Lifesci Capital - MarketBeat
Savara Inc stock (US80633A1025): Why does its rare disease focus matter more now for investors? - AD HOC NEWS
Savara Says UK Regulator Accepts MOLBREEVI Application - MyChesCo
Savara (NASDAQ:SVRA) Strengthens Market Presence In Nasdaq Today Biotech Segment - Kalkine Media
H.C. Wainwright Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Savara (NASDAQ:SVRA) Stock Price Up 2.5%Here's Why - MarketBeat
How Investors Are Reacting To Savara (SVRA) FDA Priority Review Extension For Molgramostim In Autoimmune PAP - simplywall.st
FDA extends review of Savara’s molgramostim application By Investing.com - Investing.com India
Savara, Inc. (SVRA) Stock Analysis: A Biotech Gem With 91.71% Potential Upside - DirectorsTalk Interviews
Savara (SVRA) Receives FDA Review Extension for Molgramostim App - GuruFocus
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16 - 富途牛牛
LifeSci Capital Maintains Savara(SVRA.US) With Buy Rating, Cuts Target Price to $9 - Moomoo
Savara gets FDA review extension for lead asset - MSN
Savara gets FDA review extension for lead asset (SVRA:NASDAQ) - Seeking Alpha
Savara (SVRA) Receives Three-Month Extension for BLA Review - GuruFocus
FDA Extends Review Period for Savara's Molgramostim BLA in Autoimmune PAP - National Today
Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) - BioSpace
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):